| Pair Name | Solamargine, Sorafenib | ||
| Phytochemical Name | Solamargine (PubChem CID: 73611 ) | ||
| Anticancer drug Name | Sorafenib (PubChem CID: 216239 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Solamargine, Sorafenib | |||
| Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
| Gene Regulation | Down-regulation | Expression | HOTTIP | KEGG ID N.A. |
| Down-regulation | Expression | TUG1 | hsa55000 | |
| Up-regulation | Expression | microRNA 4726 | hsa100616153 | |
| Down-regulation | Expression | MUC1 | hsa4582 | |
| In Vitro Model | Hep-G2 | Hepatoblastoma | Homo sapiens (Human) | CVCL_0027 |
| Huh-7 | Adult hepatocellular carcinoma | Homo sapiens (Human) | CVCL_0336 | |
| Result | Our study revealed that SM inhibited the growth of HCC and enhanced the anticancer effect of SF through HOTTIP-TUG1/miR-4726-5p/MUC1 signaling pathway. These findings will provide potential therapeutic targets and strategies for the treatment of HCC. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Solamargine inhibits the growth of hepatocellular carcinoma and enhances the anticancer effect of sorafenib by regulating HOTTIP-TUG1/miR-4726-5p/MUC1 pathway. Mol Carcinog. 2022 Apr;61(4):417-432. doi: 10.1002/mc.23389. | Click |
